{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959122",
  "id": "02959122",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250617",
  "time": "0936",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kth1v75ydb12.pdf",
  "summary": "### Summary of ASX Announcement:  \n**Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA**  \n\n- **Agreement Signed**: Clarity enters a **Commercial Manufacturing Agreement** with SpectronRx for **64Cu-SAR-bisPSMA**.  \n- **Capacity**: SpectronRx facility (Indiana) to produce **up to 400,000 patient-ready doses annually** by commercialization.  \n- **Scalability**: Option to expand to additional US sites, enabling **regional supply hubs**.  \n- **Distribution**: Enables nationwide (US) on-demand distribution under one roof.  \n- **Phase III Readiness**: Supports commercial rollout post-Phase III trials (**CLARIFY & AMPLIFY**) and FDA approval.  \n- **Term**: Initial **5-year agreement** (effective 17 June 2025) with standard cancellation/extension terms.  \n\n**No material financial terms or capital impacts disclosed.**  \n\n*Brevity note: Omitted operational/technical details (e.g., copper-64 half-life advantages) as non-material to immediate trading/capital decisions.*",
  "usage": {
    "prompt_tokens": 2774,
    "completion_tokens": 224,
    "total_tokens": 2998,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:41:40.963051"
}